CONTRACTING ORGANIZATION: Beth Israel Deaconess Medical Center Boston, MA 02115

Size: px
Start display at page:

Download "CONTRACTING ORGANIZATION: Beth Israel Deaconess Medical Center Boston, MA 02115"

Transcription

1 AD Award Number: W81XWH TITLE: Determination of the Dynamics, Structure, and Orientation of the Transmembrane Segment of ErbB2 in Model Membranes Using Solid-State NMR Spectroscopy PRINCIPAL INVESTIGATOR: Elvis Kwason Tiburu, Ph.D. CONTRACTING ORGANIZATION: Beth Israel Deaconess Medical Center Boston, MA REPORT DATE: March 2008 TYPE OF REPORT: Final PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

2 REPORT DOCUMENTATION PAGE Form Approved OMB No Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports ( ), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS. 1. REPORT DATE (DD-MM-YYYY) 2. REPORT TYPE Final 3. DATES COVERED (From - To) 15 SEP FEB TITLE AND SUBTITLE 5a. CONTRACT NUMBER Determination of the Dynamics, Structure, and Orientation of the Transmembrane Segment of ErbB2 in Model Membranes Using Solid-State NMR Spectroscopy 6. AUTHOR(S) Elvis Kwason Tiburu, Ph.D. etiburu@bidmc.harvard.edu 5b. GRANT NUMBER W81XWH c. PROGRAM ELEMENT NUMBER 5d. PROJECT NUMBER 5e. TASK NUMBER 5f. WORK UNIT NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER Beth Israel Deaconess Medical Center Boston, MA SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR S ACRONYM(S) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland SPONSOR/MONITOR S REPORT NUMBER(S) 12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited 13. SUPPLEMENTARY NOTES 14. ABSTRACT The objective of the proposed research was to investigate the structural properties of the transmembrane helix of the ErbB2 receptor utilizing solid-state nuclear magnetic resonance (NMR) spectroscopy and Molecular dynamics (MD) simulations. 15N Solid-state NMR results demonstrated that TM-ErbB2 has a transmembrane helical domain and that the orientation of the transmembrane domain is 24 ± 5 in shorter chain dimyristoylphosphocholine and 11 ± 3 in palmitoyloleoyphosphocholine. The orientation is dictated by the hydrophobic thickness of the synthetic phospholipid bilayers. Molecular dynamics simulations analysis demonstrated that in shorter chain lipids TM-ErbB2 also makes a tilt angle of about 28 ± 5 with respect to the bilayer normal whereas in longer chain lipids, the tilt angle was found to be 14 ± 4. We also conducted dimeirzation studies with the wild type TM-ErbB2 within the membrane bilayer environments. One of the motifs responsible for dimerization (SAVVG) was mutated to alanines whereas the other motif (GVVFG) was left intact. The GVVFG motif still had the ability to dimerize indicating that homodimerization is dictated by at least one of these motifs in full length receptor. 15. SUBJECT TERMS Solid-state NMR and molecular dynamics simulations. 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT a. REPORT U b. ABSTRACT U 18. NUMBER OF PAGES c. THIS PAGE U UU 9 19a. NAME OF RESPONSIBLE PERSON USAMRMC 19b. TELEPHONE NUMBER (include area code) Standard Form 298 (Rev. 8-98) Prescribed by ANSI Std. Z39.18

3 Table of Contents Page Introduction Body.. 4 Key Research Accomplishments... 4 Reportable Outcomes 4-7 Conclusion 7 References. 7-8 Appendices n/a

4 Determination of the Dynamics, Structure, and Orientation of the Transmembrane Segment of ErbB2 in Model Membranes Using Solid-State NMR Spectroscopy. Introduction: The malignant transformation of a normal cell into a cancer cell requires the activation of multiple oncogenes and the loss of tumor-suppressor genes. Oncogenes encode for proteins that are components of growth factor-activated intracellular signaling pathways. Activation of the epidermal growth factor family (EGFR) of receptor tyrosine kinases, ErbB1, ErbB2, ErbB3 and ErbB4, is due to ligand-induced oligomerization (1). Ligand binding to the extracellular domain of the ErbB receptors is believed to cause receptor homo- and heteroassociation, followed by trans-phosphorylation of tyrosine residues in the activation loop of the kinase domain (2). Many of these combinations preferentially involve ErbB2, a receptor for which no direct ligand has been identified. Instead, ErbB2 is activated by heterodimerization and/or multimerization with other ErbB receptors. Interestingly, ErbB2-ErbB3 heterodimers constitute a potent mitogenic combination, despite the fact that ErbB2 has no known ligand (3, 4). TM helices are involved in signal transduction, ion transmission and membrane protein folding. Over the years, computational and genetic techniques have been used to engineer antibodies that can target the cytosolic regions of receptor tyrosine kinases with the ultimate goal of disrupting oligomerized partners, but very few techniques are available to target the TM region (5, 6). Studies have shown that the TM domain of the ErbB-receptor family plays essential roles in signal transduction. For example, oligomerization of the transmembrane segment of the ErbB2 oncogene (about 23 amino acids) causes the activation of the ErbB2 receptor, which in turn leads to receptor activation within the oligomers (7, 8). The involvement of the TM domain in oligomerization is still controversial. Sequencing data has demonstrated that oncogenic p185neu differs from c-neu by a single point mutation within the TM region of the glycoprotein (7). Further studies have also provided evidence that specific interactions between the TM helices of ErbB2 can mediate dimerization and receptor activation (8). In contrast to these findings, Tanner and coworkers have argued that interactions between the TM domains do not contribute significantly to ErbB2 receptor dimerization (9). Thus, the structural picture of the TM domain of ErbB2 remains elusive despite the extensive research devoted to this important protein. The TM domains of the ErbB2 indicate two oligomerization motifs as shown in Figure 1 (10). The underlined sequences represent the Sternberg-Gullick motif and the bold sequences are related to GXXG motif. Sequence-specific association of helices is principally mediated by these two motifs. The types of interactions that can occur within these motifs to create oligomerization need to be thoroughly investigated experimentally. Therefore, integration of several research endeavors is required to understand the complete structural characteristics of the TM helices within the lipid membrane. herbb2( )-siisavvgillvvvlgvvfgili Fig 1: Sequence alignment of the TM domain of the human member of the EGFR family. The motifs identified are the underlined residues representing the Steinberg-Gullick motif and the bolded residues representing the GXXG motif. The objective of the proposed research is to investigate the structural properties of the transmembrane helix of the ErbB2 receptor utilizing solid-state nuclear magnetic resonance (NMR) spectroscopy and Molecular dynamic (MD) simulation. I am interested in using solid-state and high-resolution NMR to characterize the wild type peptide targeting the transmembrane region of the HER2/neu protein. Solid-state NMR spectroscopy is one of the techniques that can be utilized to probe membrane proteins in lipid bilayers (11, 12). Several literature sources are available that give detailed descriptions of the method and its application to membrane proteins (11-14). Whereas solid-state NMR provides information about the orientation of the protein in the membrane, highresolution NMR will provide the structure of the protein within the membrane. Both techniques will provide the information needed to define the structural features of the transmembrane segment of ErbB2/neu.

5 Body: We plan to study the transmembrane segment of HER2/neu (about 23 amino acid residues) using NMR spectroscopic techniques. The unlabeled peptide will be incorporated into aligned dimyristoylphosphatidylcholine/dihexanoylphosphatidylcholine (DMPC/DHPC) bicelles and the structure analyzed using 2-dimensional NMR. In these studies, the secondary structure of the peptide will be determined. The high-resolution NMR will also include analysis of linewidths for various bicelle sizes. In conjunction with these experiments, solid-state 2 H NMR will be performed to provide the orientation of the peptide with respect to the bilayer normal in both positive and negative aligned bicelles. In cases where we need another label to obtain some missing data, other amino acids such as valine and leucine will be labeled. The 2 H labeled peptides will be synthesized using solid phase peptide synthesis (Molecular Biology Core Facilities,Dana Farber Cancer Institute, Boston). Examination of possible oligomerization will be evaluated after the general peptide structure and orientation are resolved. Key Research Acomplishments: We have performed nuclear magnetic resonance (NMR) spectroscopy and Molecular dynamics (MD) simulations in the single membrane-spanning α-helix domain of ErbB2 designated TM-ERbB2. 2 H and 15 N Solid-state NMR results demonstrated that TM-ErbB2 has a transmembrane helical domain and that the orientation of the transmembrane domain is 24 ± 5 in shorter chain dimyristoylphosphocholine (DMPC) and 11 ± 3 in palmitoyloleoyphosphocholine (POPC). The orientation is dictated by the hydrophobic thickness of the synthetic phospholipid bilayers. Molecular dynamics simulations analysis demonstrated that in shorter chain lipids TM-ErbB2 also makes a tilt angle of about 28 ± 5 with respect to the bilayer normal whereas in longer chain lipids, the tilt angle was found to be 14 ± 4. We also conducted dimeirzation studies with the wild type TM-ErbB2 within the membrane bilayer environments. One of the motifs responsible for dimerization (SAVVG) was mutated to alanines, whereas the other motif (GVVFG) was left intact. The GVVFG motif still had the ability to dimerize. The results demonstrate that the transmembrane region of ErbB2 orientation is lipid environment dependent and that the mutant ErbB2 peptide can still undergo dimerization with only one dimerization motif. The results reveal orientation and structural information about TM-ErbB2 that we intend to investigate in vivo. We are finalizing the structural determination of the wild type ErbB2 peptides in model membrane using the solution NMR techniques. The completed structural studies as well as the in vivo studies involving breast cancer cell lines will result in significant finding suitable for publication. Reportable Outcomes: (a) Investigating the Dynamics of the Transmembrane Segment of HER2/neu in Bicelles. In these preliminary results, the secondary structure of the synthetic, and expressed peptides corresponding to the transmembrane segment of HER2/neu were analyzed by circular dichroism spectsciopy. 2 H Solid-State NMR spectroscopic studies of the HER2 peptides was also conducted in (DMPC/DHPC) bicelles. (A) 40 Mean Residue Ellipticity (deg.cm 2.dmol -1 ) Syn HER2 ExpHER2 S CD (B) SynHer2 ExpHER2 Bicelles (C) R 1Z (S -1 ) SynHER2 Bicelles ExpHER Wavelength (nm) Carbon Position Carbon Position 12 14

6 Fig 1: (A) The circular dichroism spectra of expressed/synthetic HER2/neu indicate stable secondary structural characteristics in DMPC/DHPC bicelles. (B) 2 H order parameters indicate that both HER2/neu peptides perturb the bilayer significantly as compared to the pure lipids. (C) Membrane fluidity is also significantly influenced by the HER2/neu peptides. The preliminary results indicate that expressed and synthetic HER2 are indistinguishable in terms of their structure and that both perturb the bilayer to the same extent. The bicelles of DMPC/DHPC were prepared with a molar q ratio of ~3.5 (# of moles DMPC/# of moles DHPC). The peptide concentration was optimized based upon the NMR spectral linewidths. These studies were carried out from the lipid perspective by applying the quad echo pulse sequence on the DMPC-d 54 lipids. The lipid affinities of the HER2/neu peptides were analyzed based upon their line shapes, order parameters and T 1Z relaxation measurements. Order parameters were then calculated from the quadrupolar splitting of the aligned 2 H spectra and the results compared with the pure lipids. 2 H relaxation measurements of the lipid/peptide mixtures were carried out on the pure DMPC as well as on the lipids containing HER2 peptide to determine membrane fluidity in the presence of the peptides. (b) Investigating the Orientation of the Transmembrane Segment of HER2/neu in Bicelles. The next sets of experiments were designed to determine the orientation and structure of the peptides within the bilayers with mechanically aligned phospholipids bilayers. To carry out these sets of experiments, we syntheisized specific 15 N labeled ErbB2 transmembrane peptide. For the synthetic peptide, residues were chosen such that they represent the hydrophobic region of the peptide, which is supposed to be transmembrane. The 15 N-labeled solid-state NMR spectra will reveal the orientation of the protein with respect to the bilayer normal. As shown in Figure 2D, the dynamics of the peptides within the bilayer clearly indicates an alpha helical ErbB2 as demonstrated by the chemical shift anisotropy (CSA) span of about 200 ppm. The aligned spectrum in Figure 3C represents [ 15 N-Ala 657 ]ErbB2. The residue was chosen such that the transmembrane region is almost parallel to the bilayer normal. The resonance peak at about 200 ppm indicates that Ala 657 of ErbB2 is within the phospholipids bilayer environment. Figure 2B indicates that Leu 674 of [ 15 N-Leu 674 ]ErbB2 is outside the phospholipid bilayer. Fig. 2: One-dimensional 15 N chemical shift NMR spectra of ErbB2 peptide in oriented phospholipid bilayers. (A) The spectrum corresponding to selectively [ 15 N-Ala 657 ]ErbB2 in oriented DMPC phospholipid bilayers. (B) The spectrum corresponding to selectively [ 15 N-Leu 674 ]ErbB2 in oriented DMPC phospholipid. (c) Simulation Results. A refined model of wild type human ErbB2( ) was constructed using the rat ErbB2( ) NMR structure (PDB ID: 1IIJ) as a template in prime. Residues S656-G660, forming one of two GXXXG-like recognition motifs,were then mutated to alanine. For each sequence, four peptides were arranged in a square, with 20 Å between them. Each system was solvated with simple point charge (SPC) water molecules for the wild type and for the mutant construct. Each system was minimized with steepest descents, to relax unfavorable contacts between molecules. Then, equilibration molecular dynamics (MD) with all the heavy

7 atoms in the peptide positionally restrained with a force constant of 1000 kj mol -1 nm -2, were performed for 200 ps. Unconstrained production MD was carried out for 1200 ps on each system. All simulations were carried out with the GROMACS program version In the wild type simulation, after 800 ps all four peptide strands began to oligomerize, self-aggregating via the two GXXXG-like motifs (Fig X a). The mutated peptides also oligomerized after 1000 ps, however only via the remaining GXXXG-like motif (Fig X b). Further work will simulate the mutation of the second GXXXG-like motif, residues G668-G672, to alanine. The double motif mutant will also be modeled, where ten residues S656-G660 and G668-G672 are mutated to alanine. Peptides will be modeled in a solvated lipid bilayer, to mimic their environment in the membrane. Future simulations will be longer in length and will also study the effect of peptide concentration on oligomerization. Fig 3. Two of the four (A) wild type and (B) S656-G660 alanine mutant human ErbB2( ) peptides following 1200 ps of molecular dynamics. (d) Structural Determination of ErbB2 in model Membranes. High-resolution NMR experiments were conducted on synthetic HER2/neu peptides to explore the level of oligomerization. Six residues were labeled with 15 N isotopes ( 15 N-Ile 656,-Val 659, -Leu 663, -Val 665, -Val 667, -Val 670 ). In these studies, isotropic DMPC/DHPC bicelles with a q ratio of ~ 0.5 was used to incorporate the peptide. The cross peaks in the 15 N- 1 H HSQC spectra indicate that the peptide is folded into stable secondary structures in the membrane, supporting the circular dichroism spectra in Fig 1(A). 1 H- 1 H NOESY are yet to be assigned together with the TOCSY spectra to determine the structure in the membrane. (A) (B)

8 Fig. 4: (A) 15 N- 1 H HSQC of selectively labeled synthetic HER2 peptide. (B) 1 H- 1 H NOESY spectra of synthetic HER2 peptide. The spectra were collected in DMPC/DHPC bicelles with a q ratio of ~ 0.5. The 15 N- 1 H HSQC peaks indicate that the peptide is folded into its secondary structure in DMPC/DHPC. The assignment of the cross peaks in 2B will be used to determine the structure of the peptide in the DMPC/DHPC bicelles. Conclusion: We have performed nuclear magnetic resonance (NMR) spectroscopy and Molecular dynamics (MD) simulations in the single membrane-spanning α-helix domain of ErbB2 designated TM-ERbB2. 15 N Solid-state NMR results demonstrated that TM-ErbB2 has a transmembrane helical domain and that the orientation of the transmembrane domain is 24 ± 5 in shorter chain dimyristoylphosphocholine (DMPC) and 11 ± 3 in palmitoyloleoyphosphocholine (POPC). The orientation is dictated by the hydrophobic thickness of the synthetic phospholipid bilayers. Molecular dynamics simulations analysis demonstrated that in shorter chain lipids TM-ErbB2 also makes a tilt angle of about 28 ± 5 with respect to the bilayer normal whereas in longer chain lipids, the tilt angle was found to be 14 ± 4. We also conducted dimeirzation studies with the wild type TM-ErbB2 within the membrane bilayer environments. One of the motifs responsible for dimerization (SAVVG) was mutated to alanines, whereas the other motif (GVVFG) was left intact. The GVVFG motif still had the ability to dimerize. The results demonstrate that the transmembrane region of ErbB2 orientation is lipid environment dependent and that the mutant ErbB2 peptide can still undergo dimerization with only one dimerization motif. We are in the process of conducting solution NMR experiments to elucidate the structure of the peptide within lipid bilayer environments. The present results reveal orientation and structural information about TM-ErbB2 that we intend to investigate in vivo. Now that we have evidence of the TM-ErbB2 s ability to oligomerize, the ultimate goal of this project is to test the refined oligopeptides derived from the experiments above in breast cancer cell lines to block oligomerization. The oligopeptides will be tested in four breast cancer cell lines, BT-474, SK-BR-3, T-47D and MDA-MB-453. Activation states of the HER2 receptor will be evaluated by western blotting with anti-tyr1248 ErbB2 antibody. Changes in downstream signaling induced by ErbB2 activation will be assessed by Western blotting procedures using anti-phospho-akt and anti-phospho-erk1/2 antibodies. References: 1. Harari, D., E. Tzahar, J. Romano, M. Shelly, J. H. Pierce, G. C. Andrews, and Y. Yarden Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase.. Oncogene 18: Hubbard, S. R., M. Mohammadi, and J. Schlessinger Autoregulatory mechanisms in protein tyrosine kinases.. J. Biol. Chem. 1273: Guy, P. M., J. V. Platko, L. C. Cantley, R. A. Cerione, and K. L. Carraway Insect-cell-expressed p180erbb3 possesses an impaired tyrosine kinase activity Proc. Natl. Acad. Sci. USA 91: Wehrman, T. S., W. J. Raab, C. L. Casipit, R. Doyonnas, J. H. Pomerantz, and H. M. Blau A system for quantifying dynamic protein interactions defines a role for Herceptin in Modulating ErbB2 interactions. PNAS 103: Binz, H. K., and A. Pluckthun Engineered proteins as specific binding reagents. Curr Opin Biotechnol 16: Bennasroune, A., A. Gardin, C. Auzan, E. Clauser, S. Dirrig-Grosch, M. Meira, A. Appert-Collin, D. Aunis, G. Cremel, and P. Hubert Inhibition by transmembrane peptides of chimeric insulin receptors. Cell Mol Life Sci 62: Weiner, D. B., J. Liu, J. A. Cohen, W. V. Williams, and M. I. Greene A point mutation in the neu oncogene mimics ligand induction of receptor aggregation.. Nature 339: Hynes, N. E., and D. F. Stern The biology of ErbB2/neu/HER-2 and its role in cancer.. Biochem. Biophys. Acta 1198:

9 9. Tanner, K. G., and J. Kyte Dimerization of the extracellular domain of the receptor for epidermal growth factor containing the membrane-spanning segment in response to treatment with epidermal growth factor.. J. Biol. Chem. 274: Russ, W. P., and D. M. Engelman The GxxxG motif: a framework for transmembrane helix-helix association. J Mol Biol 296: Opella, S. J NMR and membrane proteins. Nat. Struct. Biol. 4: Waugh, J. S., L. M. Huber, and U. Haeberlen Approach to high-resolution NMR in solids. Phys. Rev. Lett. 20: Tiburu, E. K., P. C. Dave, and G. A. Lorigan Solid-state 2 H NMR studies of the effects of cholesterol on the acyl chain dynamics of magnetically aligned phospholipid bilayers. Magn. Reson. Chem. 42: Wu, C. H., A. Ramamoorthy, and S. J. Opella High-resolution heteronuclear dipolar solid-state NMR spectroscopy. J. Magn. Reson. A 109: Thorgeirsson, T. E., W. Xiao, L. S. Brown, R. Needleman, J. K. Lanyi, and Y. K. Shin Transient channel-opening in bacteriorhodopsin: an EPR study. J Mol Biol 273: Tiburu, E. K., E. S. Karp, P. C. Dave, K. Damodaran, and G. A. Lorigan Investigating the dynamic properties of the transmembrane segment of phospholamban incorporated into phospholipid bilayers utilizing 2H and 15N solid-state NMR spectroscopy. Biochemistry 43:

CONTRACTING ORGANIZATION: University of California Lawrence Berkeley National Laboratory Berkeley, CA 94720

CONTRACTING ORGANIZATION: University of California Lawrence Berkeley National Laboratory Berkeley, CA 94720 AD Award Number: W81XWH-05-1-0526 TITLE: Effects of Extracellular Matix on DNA Repair in Vivo PRINCIPAL INVESTIGATOR: Aylin Rizki, Ph.D. CONTRACTING ORGANIZATION: University of California Lawrence Berkeley

More information

TITLE: Dietary Genistein and Prostate Cancer Chemoprevention

TITLE: Dietary Genistein and Prostate Cancer Chemoprevention AD AWARD NUMBER: DAMD17-02-1-0662 TITLE: Dietary Genistein and Prostate Cancer Chemoprevention PRINCIPAL INVESTIGATOR: Coral A. Lamartiniere, Ph.D. CONTRACTING ORGANIZATION: The University of Alabama at

More information

TITLE: Enhancing the Anti-Tumor Activity of ErbB Blockers with Histone Deaccetylase (HDAC) Inhibition in Prostate Cancer Cell Lines

TITLE: Enhancing the Anti-Tumor Activity of ErbB Blockers with Histone Deaccetylase (HDAC) Inhibition in Prostate Cancer Cell Lines AD Award Number: W81XWH-05-1-0040 TITLE: Enhancing the Anti-Tumor Activity of ErbB Blockers with Histone Deaccetylase (HDAC) Inhibition in Prostate Cancer Cell Lines PRINCIPAL INVESTIGATOR: Prakash Chinnaiyan,

More information

Fort Detrick, Maryland

Fort Detrick, Maryland Award Number: W81XWH-15-1-0636 TITLE: Effect of Diet on Gulf War Illness: A Pilot Study PRINCIPAL INVESTIGATOR: Ashok Tuteja, M.D. M.P.H CONTRACTING ORGANIZATION: Western Institute for Biomedical Research

More information

TITLE: Neural Protein Synuclein (SNCG) in Breast Cancer Progression

TITLE: Neural Protein Synuclein (SNCG) in Breast Cancer Progression AD AWARD NUMBER: DAMD17-01-1-0352 TITLE: Neural Protein Synuclein (SNCG) in Breast Cancer Progression PRINCIPAL INVESTIGATOR: Yangfu Jiang, M.D., Ph.D. CONTRACTING ORGANIZATION: Long Island Jewish Medical

More information

CONTRACTING ORGANIZATION: North Eastern Ohio Universities Rootstown OH 44202

CONTRACTING ORGANIZATION: North Eastern Ohio Universities Rootstown OH 44202 AD Award Number: DAMD17-03-1-0082 TITLE: Prevalence and Outcomes of Restless Legs Syndrome among Veterans PRINCIPAL INVESTIGATOR: Claire C. Bourguet, Ph.D. CONTRACTING ORGANIZATION: North Eastern Ohio

More information

TITLE: Selective Oncolytic Therapy for Hypoxic Breast Cancer Cells. CONTRACTING ORGANIZATION: Ordway Research Institute Albany, New York 12208

TITLE: Selective Oncolytic Therapy for Hypoxic Breast Cancer Cells. CONTRACTING ORGANIZATION: Ordway Research Institute Albany, New York 12208 AD Award Number: W81XWH-06-1-0586 TITLE: Selective Oncolytic Therapy for Hypoxic Breast Cancer Cells PRINCIPAL INVESTIGATOR: Michael T. Fasullo, Ph.D. CONTRACTING ORGANIZATION: Ordway Research Institute

More information

Award Number: W81XWH TITLE: Dietary Fish Oil in Reducing Bone Metastasis of Breast Cancer

Award Number: W81XWH TITLE: Dietary Fish Oil in Reducing Bone Metastasis of Breast Cancer AD Award Number: W81XWH-04-1-0693 TITLE: Dietary Fish Oil in Reducing Bone Metastasis of Breast Cancer PRINCIPAL INVESTIGATOR: Nandini Ghosh-Choudhury, Ph.D. CONTRACTING ORGANIZATION: University of Texas

More information

TITLE: New Advanced Technology to Improve Prediction and Prevention of Type 1 Diabetes

TITLE: New Advanced Technology to Improve Prediction and Prevention of Type 1 Diabetes AD Award Number: DAMD17-01-1-0009 TITLE: New Advanced Technology to Improve Prediction and Prevention of Type 1 Diabetes PRINCIPAL INVESTIGATOR: Robert A. Vigersky CONTRACTING ORGANIZATION: Children s

More information

TITLE: 64Cu-DOTA-trastuzumab PET imaging in women with HER2 overexpressing breast cancer

TITLE: 64Cu-DOTA-trastuzumab PET imaging in women with HER2 overexpressing breast cancer AD Award Number: W81XWH-10-1-0824 TITLE: 64Cu-DOTA-trastuzumab PET imaging in women with HER2 overexpressing breast cancer PRINCIPAL INVESTIGATOR: Joanne Mortimer, M.D. CONTRACTING ORGANIZATION: City of

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland Award Number: W81XWH-10-1-0593 TITLE: Probiotic (VSL#3) for Gulf War Illness PRINCIPAL INVESTIGATOR: Ashok Tuteja, M.D. M.P.H. CONTRACTING ORGANIZATION: Western Institute for Biomedical Research Salt Lake

More information

CONTRACTING ORGANIZATION: Sloan-Kettering Institute for Cancer Research New York, NY 10021

CONTRACTING ORGANIZATION: Sloan-Kettering Institute for Cancer Research New York, NY 10021 AD Award Number: DAMD17-94-J-4376 TITLE: Position Emitter I124 Iododeoxyuridine as a Tracer to Follow DNA Metabolism on Scans and in Tumor Samples in Advanced Breast Cancer: Comparison of 18F 2-Fluror-2-Deoxy-(D)-Glucose,

More information

Award Number: W81XWH

Award Number: W81XWH Award Number: W81XWH-14-2-0193 TITLE: Prevention of Bone Loss after Acute SCI by Zoledronic Acid: Durability, Effect on Bone Strength, and Use of Biomarkers to Guide Therapy PRINCIPAL INVESTIGATOR: Thomas

More information

AD (Leave blank) TITLE: Proteomic analyses of nipple fluid for early detection of breast cancer

AD (Leave blank) TITLE: Proteomic analyses of nipple fluid for early detection of breast cancer AD (Leave blank) Award Number: DAMD17-03-1-0575 TITLE: Proteomic analyses of nipple fluid for early detection of breast cancer PRINCIPAL INVESTIGATOR: Judy Garber CONTRACTING ORGANIZATION: Dana-Farber

More information

TITLE: Adipose Estrogen and Increased Breast Cancer Risk in Obesity: Regulation by Leptin and Insulin

TITLE: Adipose Estrogen and Increased Breast Cancer Risk in Obesity: Regulation by Leptin and Insulin AD Award Number: W81XWH-05-1-0497 TITLE: Adipose Estrogen and Increased Breast Cancer Risk in Obesity: Regulation by Leptin and Insulin PRINCIPAL INVESTIGATOR: Fahumiya Samad CONTRACTING ORGANIZATION:

More information

TITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer. CONTRACTING ORGANIZATION: Washington University School of Medicine St.

TITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer. CONTRACTING ORGANIZATION: Washington University School of Medicine St. AD Award Number: DAMD17-99-1-9436 TITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer PRINCIPAL INVESTIGATOR: Jeffrey A. Drebin, M.D., Ph.D. CONTRACTING ORGANIZATION: Washington University School

More information

CONTRACTING ORGANIZATION: Western Institute For Biomedical Research Salt Lake City, UT

CONTRACTING ORGANIZATION: Western Institute For Biomedical Research Salt Lake City, UT AD Award Number: W81XWH-10-1-0593 TITLE: Probiotic (VSL#3) for Gulf War Illness PRINCIPAL INVESTIGATOR: Ashok Tuteja, M.D., M.P.H. CONTRACTING ORGANIZATION: Western Institute For Biomedical Research Salt

More information

TITLE: Evaluation of DNA Methylation as a Target for Intraductal Therapy for Ductal Carcinoma in Situ of the Breast

TITLE: Evaluation of DNA Methylation as a Target for Intraductal Therapy for Ductal Carcinoma in Situ of the Breast AD AWARD NUMBER: DAMD17-02-1-0569 TITLE: Evaluation of DNA Methylation as a Target for Intraductal Therapy for Ductal Carcinoma in Situ of the Breast PRINCIPAL INVESTIGATOR: Kristin A. Skinner, M.D. CONTRACTING

More information

TITLE: Genes Associated with Food Allergy and Eosinophilic Esophagitis

TITLE: Genes Associated with Food Allergy and Eosinophilic Esophagitis AD Award Number: W81XWH-1-1-75 TITLE: Genes Associated with Food Allergy and Eosinophilic Esophagitis PRINCIPAL INVESTIGATOR: Dr. David Broide CONTRACTING ORGANIZATION: University of California, San Diego

More information

Award Number: W81XWH TITLE: Characterizing an EMT Signature in Breast Cancer. PRINCIPAL INVESTIGATOR: Melanie C.

Award Number: W81XWH TITLE: Characterizing an EMT Signature in Breast Cancer. PRINCIPAL INVESTIGATOR: Melanie C. AD Award Number: W81XWH-08-1-0306 TITLE: Characterizing an EMT Signature in Breast Cancer PRINCIPAL INVESTIGATOR: Melanie C. Bocanegra CONTRACTING ORGANIZATION: Leland Stanford Junior University Stanford,

More information

AD (Leave blank) Award Number: W81XWH TITLE: Targeting Autophagy for the Treatment of TSC and LAM. PRINCIPAL INVESTIGATOR: Elizabeth Henske

AD (Leave blank) Award Number: W81XWH TITLE: Targeting Autophagy for the Treatment of TSC and LAM. PRINCIPAL INVESTIGATOR: Elizabeth Henske AD (Leave blank) Award Number: W81XWH-12-1-0578 TITLE: Targeting Autophagy for the Treatment of TSC and LAM PRINCIPAL INVESTIGATOR: Elizabeth Henske CONTRACTING ORGANIZATION: Brigham and Women s Hospital

More information

CONTRACTING ORGANIZATION: Mount Sinai School of Medicine New York, New York

CONTRACTING ORGANIZATION: Mount Sinai School of Medicine New York, New York AD AWARD NUMBER: W81XWH-05-1-0475 TITLE: Restoration of Epithelial Polarity in Metastatic Tumors PRINCIPAL INVESTIGATOR: Sergei Sokol, Ph.D. CONTRACTING ORGANIZATION: Mount Sinai School of Medicine New

More information

Award Number: W81XWH TITLE: A Novel Membrane-Permeable, Breast-Targeting, Pro-Apoptotic Peptide for Treatment of Breast Cancer

Award Number: W81XWH TITLE: A Novel Membrane-Permeable, Breast-Targeting, Pro-Apoptotic Peptide for Treatment of Breast Cancer AD Award Number: W81XWH-04-1-0705 TITLE: A Novel Membrane-Permeable, Breast-Targeting, Pro-Apoptotic Peptide for Treatment of Breast Cancer PRINCIPAL INVESTIGATOR: Bin Guo, Ph.D. CONTRACTING ORGANIZATION:

More information

TITLE: Induction of Ephs/Ephrins-Mediated Tumor Cells-Endothelial Cells Repulsion as an Anti-Cancer Therapeutic Approach

TITLE: Induction of Ephs/Ephrins-Mediated Tumor Cells-Endothelial Cells Repulsion as an Anti-Cancer Therapeutic Approach AD Award Number: W81XWH-04-1-0661 TITLE: Induction of Ephs/Ephrins-Mediated Tumor Cells-Endothelial Cells Repulsion as an Anti-Cancer Therapeutic Approach PRINCIPAL INVESTIGATOR: Gerald Batist, M.D. CONTRACTING

More information

CONTRACTING ORGANIZATION: Oregon Health & Science University Beaverton, OR 97006

CONTRACTING ORGANIZATION: Oregon Health & Science University Beaverton, OR 97006 AD Award Number: W81XWH-07-1-0423 TITLE: Role of Hyaluronan in Schwannoma Growth PRINCIPAL INVESTIGATOR: Larry S. Sherman, Ph.D. CONTRACTING ORGANIZATION: Oregon Health & Science University Beaverton,

More information

Approved for public release; distribution unlimited

Approved for public release; distribution unlimited Award Number: W81XWH-16-1-0763 TITLE: Increasing Bone Mass and Bone Strength in Individuals with Chronic Spinal Cord Injury: Maximizing Response to Therapy PRINCIPAL INVESTIGATOR: Thomas J. Schnitzer,

More information

TITLE: Breast Tumor-Generated Type 1 Collagen Breakdown Fragments Act as Matrikines to Drive Osteolysis

TITLE: Breast Tumor-Generated Type 1 Collagen Breakdown Fragments Act as Matrikines to Drive Osteolysis AD Award Number: W81XWH-08-1-0639 TITLE: Breast Tumor-Generated Type 1 Collagen Breakdown Fragments Act as Matrikines to Drive Osteolysis PRINCIPAL INVESTIGATOR: Ching Hua William Wu PhD. CONTRACTING ORGANIZATION:

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AD Award Number: W81XWH-06-1-0093 TITLE: An Epigenetic Link to Prostate Cancer PRINCIPAL INVESTIGATOR: Raphael F Margueron, Ph.D. CONTRACTING ORGANIZATION: University of Medicine and Dentistry of New Jersey

More information

Award Number: W81XWH TITLE: Global Positioning Systems (GPS) Technology to Study Vector-Pathogen-Host Interactions

Award Number: W81XWH TITLE: Global Positioning Systems (GPS) Technology to Study Vector-Pathogen-Host Interactions Award Number: W81XWH-11-2-0175 TITLE: Global Positioning Systems (GPS) Technology to Study Vector-Pathogen-Host Interactions PRINCIPAL INVESTIGATOR: Timothy P. Endy MD, MPH CONTRACTING ORGANIZATION: SUNY

More information

TITLE: Effect of MUC1 Expression on EGFR Endocytosis and Degradation in Human Breast Cancer Cell Lines

TITLE: Effect of MUC1 Expression on EGFR Endocytosis and Degradation in Human Breast Cancer Cell Lines AD AWARD NUMBER: W81XWH-06-1-0464 TITLE: Effect of MUC1 Expression on EGFR Endocytosis and Degradation in Human Breast Cancer Cell Lines PRINCIPAL INVESTIGATOR: Rachid M El Bejjani CONTRACTING ORGANIZATION:

More information

AWARD NUMBER: W81XWH TITLE: Gulf War Illness as a Brain Autoimmune Disorder. PRINCIPAL INVESTIGATOR: Apostolos Georgopoulos, MD, PhD

AWARD NUMBER: W81XWH TITLE: Gulf War Illness as a Brain Autoimmune Disorder. PRINCIPAL INVESTIGATOR: Apostolos Georgopoulos, MD, PhD AWARD NUMBER: W81XWH-15-1-0520 TITLE: Gulf War Illness as a Brain Autoimmune Disorder PRINCIPAL INVESTIGATOR: Apostolos Georgopoulos, MD, PhD CONTRACTING ORGANIZATION: Regents University of Minnesota Minneapolis,

More information

TITLE: Investigation of the Akt/PKB Kinase in the Development of Hormone-Independent Prostate Cancer

TITLE: Investigation of the Akt/PKB Kinase in the Development of Hormone-Independent Prostate Cancer AD Award Number: TITLE: Investigation of the Akt/PKB Kinase in the Development of Hormone-Independent Prostate Cancer PRINCIPAL INVESTIGATOR: Linda A. degraffenried, Ph.D. CONTRACTING ORGANIZATION: The

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, MD

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, MD AD Award Number: W81XWH-11-1-0126 TITLE: Chemical strategy to translate genetic/epigenetic mechanisms to breast cancer therapeutics PRINCIPAL INVESTIGATOR: Xiang-Dong Fu, PhD CONTRACTING ORGANIZATION:

More information

TITLE: Interchromosomal Associations that Alter NF1 Gene Expression Can Modify Clinical Manifestations of Neurofibromatosis 1. Palo Alto, CA 94304

TITLE: Interchromosomal Associations that Alter NF1 Gene Expression Can Modify Clinical Manifestations of Neurofibromatosis 1. Palo Alto, CA 94304 AD AWARD NUMBER: W81XWH-06-1-0695 TITLE: Interchromosomal Associations that Alter NF1 Gene Expression Can Modify Clinical Manifestations of Neurofibromatosis 1 PRINCIPAL INVESTIGATOR: Andrew R. Hoffman,

More information

TITLE: The Role Of Alternative Splicing In Breast Cancer Progression

TITLE: The Role Of Alternative Splicing In Breast Cancer Progression AD Award Number: W81XWH-06-1-0598 TITLE: The Role Of Alternative Splicing In Breast Cancer Progression PRINCIPAL INVESTIGATOR: Klemens J. Hertel, Ph.D. CONTRACTING ORGANIZATION: University of California,

More information

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-14-1-0503 TITLE: Effect of Diabetes and Obesity on Disparities in Prostate Cancer Outcomes PRINCIPAL INVESTIGATOR: Bettina F. Drake, MPH, PhD CONTRACTING ORGANIZATION: Washington University

More information

TITLE: Oxidative Stress, DNA Repair and Prostate Cancer Risk. PRINCIPAL INVESTIGATOR: Hua Zhao, Ph.D.

TITLE: Oxidative Stress, DNA Repair and Prostate Cancer Risk. PRINCIPAL INVESTIGATOR: Hua Zhao, Ph.D. AD Award Number: W81XWH-08-1-0416 TITLE: Oxidative Stress, DNA Repair and Prostate Cancer Risk PRINCIPAL INVESTIGATOR: Hua Zhao, Ph.D. CONTRACTING ORGANIZATION: Health Research Inc Buffalo, NY 14263 REPORT

More information

CONTRACTING ORGANIZATION: Regents of the University of Michigan Ann Arbor, MI 48109

CONTRACTING ORGANIZATION: Regents of the University of Michigan Ann Arbor, MI 48109 AWARD NUMBER: W81XWH-13-1-0463 TITLE: The Ketogenic Diet and Potassium Channel Function PRINCIPAL INVESTIGATOR: Dr. Geoffrey Murphy CONTRACTING ORGANIZATION: Regents of the University of Michigan Ann Arbor,

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AD Award Number: W81XWH-12-1-0248 TITLE: Targeted Inhibition of Tyrosine Kinase-Mediated Epigenetic Alterations to Prevent Resurgence of Castration-Resistant Prostate Cancer PRINCIPAL INVESTIGATOR: Dr.

More information

TITLE: Inhibitors of Histone Deacetylases for Radiosensitization of Prostate Cancer

TITLE: Inhibitors of Histone Deacetylases for Radiosensitization of Prostate Cancer AD Award Number: W81XWH-04-1-0170 TITLE: Inhibitors of Histone Deacetylases for Radiosensitization of Prostate Cancer PRINCIPAL INVESTIGATOR: Mira O. Jung, Ph.D. CONTRACTING ORGANIZATION: Georgetown University

More information

AD (Leave blank) PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

AD (Leave blank) PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AD (Leave blank) Award Number: W81XWH-06-2-0038 TITLE:T Cell Lipid rafts and complement Ligands for Diagnosis and Monitoring PRINCIPAL INVESTIGATOR: George C. Tsokos, MD CONTRACTING ORGANIZATION: Beth

More information

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer AD Award Number: W8XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke Ph.D. CONTRACTING ORGANIZATION: Johns Hopkins

More information

TITLE: A Tissue Engineering Approach to Study the Progression of Breast Tumor Metastasis in Bone

TITLE: A Tissue Engineering Approach to Study the Progression of Breast Tumor Metastasis in Bone AD AWARD NUMBER: W81XWH-04-1-0749 TITLE: A Tissue Engineering Approach to Study the Progression of Breast Tumor Metastasis in Bone PRINCIPAL INVESTIGATOR: Mingxin Che, M.D., Ph.D. Daotai Nie, Ph.D. CONTRACTING

More information

La Jolla, CA Approved for Public Release; Distribution Unlimited

La Jolla, CA Approved for Public Release; Distribution Unlimited AD Award Number: TITLE: Suppression of Breast Cancer Progression by Tissue Factor PRINCIPAL INVESTIGATOR: Wolfram Ruf, M.D. CONTRACTING ORGANIZATION: The Scripps Research Institute La Jolla, CA 92037 REPORT

More information

TITLE: The Role of Constitutively Active Prolactin Receptors in the Natural History of Breast Cancer

TITLE: The Role of Constitutively Active Prolactin Receptors in the Natural History of Breast Cancer AD Award Number: W81XWH-06-1-0448 TITLE: The Role of Constitutively Active Prolactin Receptors in the Natural History of Breast Cancer PRINCIPAL INVESTIGATOR: Kuang-tzu Huang CONTRACTING ORGANIZATION:

More information

CONTRACTING ORGANIZATION: Cold Spring Harbor Laboratory Cold Spring Harbor, NY 11724

CONTRACTING ORGANIZATION: Cold Spring Harbor Laboratory Cold Spring Harbor, NY 11724 AD Award Number: W81XWH-10-1-0450 TITLE: The role of NF1 in memory retrieval PRINCIPAL INVESTIGATOR: Yi Zhong, Ph.D. CONTRACTING ORGANIZATION: Cold Spring Harbor Laboratory Cold Spring Harbor, NY 11724

More information

TITLE: The Importance of Autophagy in Breast Cancer Development and Treatment

TITLE: The Importance of Autophagy in Breast Cancer Development and Treatment AD Award Number: W81XWH-06-1-0557 TITLE: The Importance of Autophagy in Breast Cancer Development and Treatment PRINCIPAL INVESTIGATOR: Jin-Ming Yang, Ph.D. CONTRACTING ORGANIZATION: University of Medicine

More information

TITLE: The Role of hcdc4 as a Tumor Suppressor Gene in Genomic Instability Underlying Prostate Cancer

TITLE: The Role of hcdc4 as a Tumor Suppressor Gene in Genomic Instability Underlying Prostate Cancer AD Award Number: TITLE: The Role of hcdc4 as a Tumor Suppressor Gene in Genomic Instability Underlying Prostate Cancer PRINCIPAL INVESTIGATOR: Audrey van Drogen, Ph.D. CONTRACTING ORGANIZATION: Sidney

More information

TITLE: Role of ADAM15 in Tumor/Endothelial Interactions Prostate Cancer Regression

TITLE: Role of ADAM15 in Tumor/Endothelial Interactions Prostate Cancer Regression AD Award Number: W81XWH-07-1-0030 TITLE: Role of ADAM15 in Tumor/Endothelial Interactions Prostate Cancer Regression PRINCIPAL INVESTIGATOR: Mark L. Day CONTRACTING ORGANIZATION: University of Michigan

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AD Award Number: DAMD17-03-1-0392 TITLE: The Role of Notch Signaling Pathway in Breast Cancer Pathogenesis PRINCIPAL INVESTIGATOR: Annapoorni Rangarajan, Ph.D. CONTRACTING ORGANIZATION: Indian Institute

More information

Sphingosine-1-Phosphate Receptor Subtype 3: A Novel Therapeutic Target of K-Ras Mutant Driven Non-Small Cell Lung Carcinoma

Sphingosine-1-Phosphate Receptor Subtype 3: A Novel Therapeutic Target of K-Ras Mutant Driven Non-Small Cell Lung Carcinoma AWARD NUMBER: W81XWH-14-1-0346 TITLE: Sphingosine-1-Phosphate Receptor Subtype 3: A Novel Therapeutic Target of K-Ras Mutant Driven Non-Small Cell Lung Carcinoma PRINCIPAL INVESTIGATOR: Lee, Menq-Jer,

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AD Award Number: TITLE: Suppression of Breast Cancer Progression by Tissue Factor PRINCIPAL INVESTIGATOR: Wolfram Ruf, M.D. CONTRACTING ORGANIZATION: The Scripps Research Institute La Jolla, CA 92037 REPORT

More information

TITLE: Identification of New Serum Biomarkers for Early Breast Cancer Diagnosis and Prognosis Using Lipid Microarrays.

TITLE: Identification of New Serum Biomarkers for Early Breast Cancer Diagnosis and Prognosis Using Lipid Microarrays. AD Award Number: W81XWH-06-1-0690 TITLE: Identification of New Serum Biomarkers for Early Breast Cancer Diagnosis and Prognosis Using Lipid Microarrays. PRINCIPAL INVESTIGATOR: Guangwei Du, Ph.D. CONTRACTING

More information

TITLE: Hyaluronic acid is overexpressed in fibrotic lung tissue and promotes collagen expression

TITLE: Hyaluronic acid is overexpressed in fibrotic lung tissue and promotes collagen expression AD Award Number: W81XWH-07-1-0253 TITLE: Hyaluronic acid is overexpressed in fibrotic lung tissue and promotes collagen expression PRINCIPAL INVESTIGATOR: Pal Gooz, M.D. CONTRACTING ORGANIZATION: Medical

More information

TITLE: Estrogen-DNA Adducts as Novel Biomarkers for Ovarian Cancer Risk and for Use in Prevention

TITLE: Estrogen-DNA Adducts as Novel Biomarkers for Ovarian Cancer Risk and for Use in Prevention AD (Leave blank) Award Number: W81XWH-10-1-0175 TITLE: Estrogen-DNA Adducts as Novel Biomarkers for Ovarian Cancer Risk and for Use in Prevention PRINCIPAL INVESTIGATOR: Eleanor G. Rogan, Ph.D. CONTRACTING

More information

Detection of Prostate Cancer Progression by Serum DNA Integrity

Detection of Prostate Cancer Progression by Serum DNA Integrity AD Award Number: TITLE: Detection of Prostate Cancer Progression by Serum DNA Integrity PRINCIPAL INVESTIGATOR: Dave S.B. Hoon, Ph.D. CONTRACTING ORGANIZATION: John Wayne Cancer Institute Santa Monica,

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AD Award Number: W81XWH-05-1-0045 TITLE: MT 2A Phosphorylation by PKC Mu/PKD Influences Chemosensitivity to Cisplatin in Prostate Cancer PRINCIPAL INVESTIGATOR: Kethandapatti Balaji, M.D. CONTRACTING ORGANIZATION:

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AD Award Number: W81XWH-05-1-0262 TITLE: Role of CDK4 in Breast Development and Cancer PRINCIPAL INVESTIGATOR: Haritha Reddy CONTRACTING ORGANIZATION: Temple University Philadelphia PA 19122-6024 REPORT

More information

TITLE: Overcoming Resistance to Inhibitors of the Akt Protein Kinase by Modulation of the Pim Kinase Pathway

TITLE: Overcoming Resistance to Inhibitors of the Akt Protein Kinase by Modulation of the Pim Kinase Pathway AWARD NUMBER: W81XWH-12-1-0560 TITLE: Overcoming Resistance to Inhibitors of the Akt Protein Kinase by Modulation of the Pim Kinase Pathway PRINCIPAL INVESTIGATOR: Andrew S. Kraft, MD CONTRACTING ORGANIZATION:

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AD Award Number: W81XWH-13-2-0032 TITLE: Increasing Treatment Seeking Among At-Risk Service Members Returning from Warzones PRINCIPAL INVESTIGATOR: Tracy Stecker, PhD CONTRACTING ORGANIZATION: Dartmouth

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AD Award Number: W81XWH-06-1-0524 TITLE: Elucidating and Modeling Irradiation Effects on Centrosomal and Chromosomal Stability within Breast Cancer PRINCIPAL INVESTIGATOR: Christopher A. Maxwell, Ph.D.

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AD Award Number: W81XWH-04-1-0618 TITLE: Are Breast Tumor Stem Cells Responsible for Metastasis and Angiogenesis PRINCIPAL INVESTIGATOR: Quintin Pan, Ph.D. CONTRACTING ORGANIZATION: University of Michigan

More information

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-14-1-0503 TITLE: Effect of Diabetes and Obesity on Disparities in Prostate Cancer Outcomes PRINCIPAL INVESTIGATOR: Bettina F. Drake, MPH, PhD CONTRACTING ORGANIZATION: Washington University

More information

AWARD NUMBER: W81XWH TITLE: Androgen Deprivation Therapy and Cognitive Impairment. PRINCIPAL INVESTIGATOR: Robert N. Pechnick, Ph.D.

AWARD NUMBER: W81XWH TITLE: Androgen Deprivation Therapy and Cognitive Impairment. PRINCIPAL INVESTIGATOR: Robert N. Pechnick, Ph.D. AWARD NUMBER: W81XWH-16-1-0429 TITLE: Androgen Deprivation Therapy and Cognitive Impairment PRINCIPAL INVESTIGATOR: Robert N. Pechnick, Ph.D. CONTRACTING ORGANIZATION: Western University of Health Sciences

More information

TITLE: The Role of HOX Proteins in Androgen-Independent Prostate Cancer

TITLE: The Role of HOX Proteins in Androgen-Independent Prostate Cancer AD Award Number: W81XWH-6-1-64 TITLE: The Role of HOX Proteins in Androgen-Independent Prostate Cancer PRINCIPAL INVESTIGATOR: Sunshine Daddario, B.A. CONTRACTING ORGANIZATION: University of Colorado Health

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-14-1-0546 TITLE: Assessing EphA2 and Ephrin-A as Novel Diagnostic and Prognostic Biomarkers of Prostate Cancer PRINCIPAL INVESTIGATOR: Carvell Tran Nguyen, MD PhD CONTRACTING ORGANIZATION:

More information

TITLE: Short-Term Exercise and Prostate Cancer Prevention in African American Men. CONTRACTING ORGANIZATION: Howard University Washington DC 20059

TITLE: Short-Term Exercise and Prostate Cancer Prevention in African American Men. CONTRACTING ORGANIZATION: Howard University Washington DC 20059 AD Award Number: W81XWH-05-1-0366 TITLE: Short-Term Exercise and Prostate Cancer Prevention in African American Men PRINCIPAL INVESTIGATOR: Teletia R. Taylor, Ph.D. CONTRACTING ORGANIZATION: Howard University

More information

AWARD NUMBER: W81XWH TITLE: Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury with Deep Brain Stimulation

AWARD NUMBER: W81XWH TITLE: Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury with Deep Brain Stimulation AWARD NUMBER: W81XWH-12-1-0559 TITLE: Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury with Deep Brain Stimulation PRINCIPAL INVESTIGATOR: Jonathan R. Jagid, M.D. CONTRACTING ORGANIZATION:

More information

CONTRACTING ORGANIZATION: Oregon Health and Science University Portland, Oregon

CONTRACTING ORGANIZATION: Oregon Health and Science University Portland, Oregon AD AWARD NUMBER: W81XWH-05-1-0152 TITLE: A Novel Mechanism of Androgen Receptor Action PRINCIPAL INVESTIGATOR: Charles T. Roberts, Jr., Ph.D. CONTRACTING ORGANIZATION: Oregon Health and Science University

More information

CONTRACTING ORGANIZATION: Johns Hopkins Bloomberg School of Public Health

CONTRACTING ORGANIZATION: Johns Hopkins Bloomberg School of Public Health AD Award Number: W81XWH-12-1-0170 TITLE: Prospective Evaluation of Intraprostatic Inflammation and Focal Atrophy as a Predictor of Risk of High-Grade Prostate Cancer and Recurrence after Prostatectomy

More information

TITLE: Properties of Leukemia Stem Cells in a Novel Model of CML Progression to Lymphoid Blast Crisis

TITLE: Properties of Leukemia Stem Cells in a Novel Model of CML Progression to Lymphoid Blast Crisis AD Award Number: W81XWH-05-1-0608 TITLE: Properties of Leukemia Stem Cells in a Novel Model of CML Progression to Lymphoid Blast Crisis PRINCIPAL INVESTIGATOR: Craig T. Jordan, Ph.D. CONTRACTING ORGANIZATION:

More information

CONTRACTING ORGANIZATION: Oregon Health & Science University Portland OR 97239

CONTRACTING ORGANIZATION: Oregon Health & Science University Portland OR 97239 AWARD NUMBER: W81XWH-16-1-0300 TITLE: Metformin Therapy for Fanconis Anemia PRINCIPAL INVESTIGATOR: Markus Grompe CONTRACTING ORGANIZATION: Oregon Health & Science University Portland OR 97239 REPORT DATE:

More information

Award Number: W81XWH TITLE: Regenerative Stem Cell Therapy for Breast Cancer Bone Metastasis

Award Number: W81XWH TITLE: Regenerative Stem Cell Therapy for Breast Cancer Bone Metastasis AD Award Number: W81XWH-11-1-593 TITLE: Regenerative Stem Cell Therapy for Breast Cancer Bone Metastasis PRINCIPAL INVESTIGATOR: Selvarangan Ponnazhagan, Ph.D. CONTRACTING ORGANIZATION: University of Alabama

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-15-1-0154 TITLE: Efficacy of the Direct Instruction Language for Learning (DI-LL) Program to Promote Expressive and Receptive Language in Children with Autism Spectrum Disorder PRINCIPAL

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-13-1-0463 TITLE: The Ketogenic Diet and Potassium Channel Function PRINCIPAL INVESTIGATOR: Dr. Geoffrey Murphy CONTRACTING ORGANIZATION: University of Michigan Ann Arbor, MI 48109

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-13-1-0421 TITLE: The Fanconi Anemia BRCA Pathway as a Predictor of Benefit from Bevacizumab in a Large Phase III Clinical Trial in Ovarian Cancer PRINCIPAL INVESTIGATOR: Elizabeth

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-13-1-0203 TITLE: Targeting almitoyl cyltransferases in NRAS- elanoma PRINCIPAL INVESTIGATOR: Xu Wu, Ph.D. CONTRACTING ORGANIZATION: Massachusetts General Hospital, Boston, MA 02114

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AD Award Number: TITLE: PRINCIPAL INVESTIGATOR: Jeremy Chien, PhD CONTRACTING ORGANIZATION: Mayo Clinic, REPORT DATE: September 2012 TYPE OF REPORT: Annual PREPARED FOR: U.S. Army Medical Research and

More information

TITLE: Effect of COX-2 (PGE2) and IL-6 on Prostate Cancer Bone Mets

TITLE: Effect of COX-2 (PGE2) and IL-6 on Prostate Cancer Bone Mets AD Award Number: W81XWH-05-1-0166 TITLE: Effect of COX-2 (PGE2) and IL-6 on Prostate Cancer Bone Mets PRINCIPAL INVESTIGATOR: Alice C. Levine, M.D. CONTRACTING ORGANIZATION: Mount Sinai School of Medicine

More information

TITLE: A PSCA Promoter Based Avian Retroviral Transgene Model of Normal and Malignant Prostate

TITLE: A PSCA Promoter Based Avian Retroviral Transgene Model of Normal and Malignant Prostate AD Award Number: DAMD17-03-1-0163 TITLE: A PSCA Promoter Based Avian Retroviral Transgene Model of Normal and Malignant Prostate PRINCIPAL INVESTIGATOR: Robert Reiter, M.D. CONTRACTING ORGANIZATION: The

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AD Award Number: W81XWH-12-1-0337 TITLE: Molecular Innovations Toward Theranostics of Aggressive Prostate Cancer PRINCIPAL INVESTIGATOR: Hsieh, Jer-Tsong CONTRACTING ORGANIZATION: University of Texas Southwestern

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AWARD NUMBER: W81XWH-13-1-0486 TITLE: Early Recognition of Chronic Traumatic Encephalopathy Through FDDNP PET Imaging PRINCIPAL INVESTIGATOR: Charles Bernick, MD, MPH CONTRACTING ORGANIZATION: Cleveland

More information

CONTRACTING ORGANIZATION: Fred Hutchinson Cancer Research Center Seattle, WA 98109

CONTRACTING ORGANIZATION: Fred Hutchinson Cancer Research Center Seattle, WA 98109 AWARD NUMBER: W81XWH-10-1-0711 TITLE: Transgenerational Radiation Epigenetics PRINCIPAL INVESTIGATOR: Christopher J. Kemp, Ph.D. CONTRACTING ORGANIZATION: Fred Hutchinson Cancer Research Center Seattle,

More information

TITLE: Homeostatic and Circadian Abnormalities in Sleep and Arousal in Gulf War Syndrome

TITLE: Homeostatic and Circadian Abnormalities in Sleep and Arousal in Gulf War Syndrome Award Number: W81XWH-10-2-0129 TITLE: Homeostatic and Circadian Abnormalities in Sleep and Arousal in Gulf War Syndrome PRINCIPAL INVESTIGATOR: Timothy M. Juergens, M.D. CONTRACTING ORGANIZATION: University

More information

TITLE: Effect of Reminder Telephone Calls on Mammography Compliance in High Risk

TITLE: Effect of Reminder Telephone Calls on Mammography Compliance in High Risk AD Award Number: W81XWH-04-1-0465 TITLE: Effect of Reminder Telephone Calls on Mammography Compliance in High Risk PRINCIPAL INVESTIGATOR: Carrie Snyder CONTRACTING ORGANIZATION: Creighton University Omaha,

More information

CONTRACTING ORGANIZATION: University of Illinois Chicago, IL

CONTRACTING ORGANIZATION: University of Illinois Chicago, IL AD Award Number: W81XWH-05-1-0009 TITLE: Selenoproteins and Prostate Cancer PRINCIPAL INVESTIGATOR: Veda Navsariwala, Ph.D. CONTRACTING ORGANIZATION: University of Illinois Chicago, IL 60612-7205 REPORT

More information

CONTRACTING ORGANIZATION: University of Minnesota St Paul, MN 55108

CONTRACTING ORGANIZATION: University of Minnesota St Paul, MN 55108 AD Award Number: W81XWH-06-1-0778 TITLE: Dietary Fat, Eicosanoids and Breast Cancer Risk PRINCIPAL INVESTIGATOR: Lindsay Orr CONTRACTING ORGANIZATION: University of Minnesota St Paul, MN 55108 REPORT DATE:

More information

TITLE: Long Term Outcomes of BRCA1/BRCA2 Mutation Testing. CONTRACTING ORGANIZATION: Georgetown University Washington, DC

TITLE: Long Term Outcomes of BRCA1/BRCA2 Mutation Testing. CONTRACTING ORGANIZATION: Georgetown University Washington, DC AD AWARD NUMBER: DAMD17-03-1-0553 TITLE: Long Term Outcomes of BRCA1/BRCA2 Mutation Testing PRINCIPAL INVESTIGATOR: Marc D. Schwartz, Ph.D. CONTRACTING ORGANIZATION: Georgetown University Washington, DC

More information

TITLE: "Impact of Obesity on Tamoxifen Chemoprevention in a Model of Ductal Carcinoma in Situ"

TITLE: Impact of Obesity on Tamoxifen Chemoprevention in a Model of Ductal Carcinoma in Situ AD Award Number: W81XWH-09-1-0720 TITLE: "Impact of Obesity on Tamoxifen Chemoprevention in a Model of Ductal Carcinoma in Situ" PRINCIPAL INVESTIGATOR: Sarah Dunlap-Smith, Ph.D. CONTRACTING ORGANIZATION:

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AD Award Number: W81XWH- TITLE: PRINCIPAL INVESTIGATOR: CONTRACTING ORGANIZATION: REPORT DATE: TYPE OF REPORT: Annual PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

More information

Award Number: W81XWH

Award Number: W81XWH AD Award Number: W81XWH-08-2-0050 TITLE: PT073853: Mild TBI Following Exposure to Explosive Devices: Device Characteristics, Neuropsychological Functioning, and Symptoms of Post-Traumatic Stress Disorder

More information

TITLE: Harnessing GPR17 Biology for Treating Demyelinating Disease

TITLE: Harnessing GPR17 Biology for Treating Demyelinating Disease AD Award Number: W81XWH-10-1-0723 TITLE: Harnessing GPR17 Biology for Treating Demyelinating Disease PRINCIPAL INVESTIGATOR: Qing Lu, Ph.D. CONTRACTING ORGANIZATION: University of Texas Southwestern Medical

More information

CONTRACTING ORGANIZATION: University of Texas M.D. Anderson Cancer Center Houston, TX 77030

CONTRACTING ORGANIZATION: University of Texas M.D. Anderson Cancer Center Houston, TX 77030 AD Award Number: W81XWH-7-1-345 TITLE: Second-Generation Therapeutic DNA Lymphoma Vaccines PRINCIPAL INVESTIGATOR: Larry W. Kwak, M.D., Ph.D. CONTRACTING ORGANIZATION: University of Texas M.D. Anderson

More information

CONTRACTING ORGANIZATION: Rush University Medical Center Chicago, IL 60612

CONTRACTING ORGANIZATION: Rush University Medical Center Chicago, IL 60612 AD Award Number: W81XWH-11-1-0302 TITLE: Yin and Yang of Heparanase in breast Tumor Initiation PRINCIPAL INVESTIGATOR: Xiulong Xu, Ph.D. CONTRACTING ORGANIZATION: Rush University Medical Center Chicago,

More information

TITLE: Effects of Tobacco Smoke (TS) on growth of clear cell renal cell carcinoma (ccrcc)

TITLE: Effects of Tobacco Smoke (TS) on growth of clear cell renal cell carcinoma (ccrcc) AD Award Number: W81XWH-14-1-0347 TITLE: Effects of Tobacco Smoke (TS) on growth of clear cell renal cell carcinoma (ccrcc) PRINCIPAL INVESTIGATOR: Maria F. Czyzyk-Krzeska CONTRACTING ORGANIZATION: University

More information

TITLE: Targeting the Immune System s Natural Response to Cell Death to Improve Therapeutic Response in Breast Cancers

TITLE: Targeting the Immune System s Natural Response to Cell Death to Improve Therapeutic Response in Breast Cancers AD Award Number: W81XWH-13-1-0158 TITLE: Targeting the Immune System s Natural Response to Cell Death to Improve Therapeutic Response in Breast Cancers PRINCIPAL INVESTIGATOR: Rebecca S. Cook CONTRACTING

More information

Approved for public release; distribution unlimited

Approved for public release; distribution unlimited Award Number: W81XWH-10-1-1021 TITLE: Post-traumatic Headache and Psychological Health: Mindfulness Training for Mild Traumatic Brain Injury PRINCIPAL INVESTIGATOR: Sutapa Ford, PhD CONTRACTING ORGANIZATION:

More information

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland AD Award Number: W81XWH-12-1-0225 TITLE: Epstein Barr virus and blood brain barrier in Multiple Sclerosis PRINCIPAL INVESTIGATOR: Luwen Zhang CONTRACTING ORGANIZATION: University of Nebraska Lincoln, NE

More information

CONTRACTING ORGANIZATION: Vanderbilt University Medical Center Nashville, TN

CONTRACTING ORGANIZATION: Vanderbilt University Medical Center Nashville, TN AD Award Number: W81XWH-04-1-0867 TITLE: A Myc-Driven in Vivo Model of Human Prostate Cancer PRINCIPAL INVESTIGATOR: Simon W. Hayward, Ph.D. CONTRACTING ORGANIZATION: Vanderbilt University Medical Center

More information

CONTRACTING ORGANIZATION: Southern Illinois University School of Medicine, Springfield, IL

CONTRACTING ORGANIZATION: Southern Illinois University School of Medicine, Springfield, IL Award Number: W81XWH-14-1-0019 TITLE: Identification and Reconstruction of Prostate Tumor-Suppressing Exosomes for Therapeutic Applications PRINCIPAL INVESTIGATOR: Daotai Nie CONTRACTING ORGANIZATION:

More information